US › Healthcare

Immatics NV (IMTX)

US · Healthcare · Biotechnology

$9.38+3.99%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$7.6M

Revenue YoY

-59.0%

Net profit

$-57.8M

Profit YoY

-45.1%

EPS

$-0.51

EPS estimate

$-0.44

Net margin

-759.5%

EPS came in at -0.51 against a street estimate of -0.44 — a miss of 15.9%.

Key statistics

Market cap

$1.18B

Forward P/E

0.0

P/B

2.26

Book value

$3.79

EPS (TTM)

$-1.96

52-week high

$12.41

52-week low

$5.05

50-day MA

$9.80

200-day MA

$10.09

Beta

1.32

Analyst view

Analysts rate Immatics NV a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $17.87.

Shareholding

Insiders

17.58%

Institutions

79.61%

Largest institutional holders

Fund	Stake
T. Rowe Price Investment Management,Inc.	15.84%
RTW INVESTMENTS, LLC	9.42%
Suvretta Capital Management, LLC	8.19%
Baker Bros Advisors LP	7.99%
Perceptive Advisors LLC	7.60%
The Toronto-Dominion Bank	5.44%
Vestal Point Capital LP	4.52%
Jefferies Financial Group Inc	3.70%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Immatics NV — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.